Answers are grounded in this paper and cite their sources.
We examined the aggregation responses of normal neutrophils treated with the murine monoclonal antibody (MoAb) 60.3. Addition of MoAb 60.3 to normal neutrophils produced dose-dependent inhibition of neutrophil aggregation in response to phorbol myristate acetate, zymosan-activated plasma, and N-formyl-methionylleucylphenylalanine. We conclude that the membrane glycoprotein complex recognized by MoAb 60.3--designated CDw18--is required for neutrophil-neutrophil aggregation in vitro.
No takes yet. Share an insight, caveat, or question.
Schwartz et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: